Market Overview

Mylan Pharma Wins Final FDA Approval for ANDA for Phenytoin Chewable Tablets, 50 mg

Share:
Related MYL
M&A Potential With This Healthcare ETF
Benzinga's M&A Chatter for Monday May 16, 2016
Growing Generic Drug Market a Good Opportuity for — India Firms (GuruFocus)
Related PFE
JPMorgan: Monsanto Shares Could Hit $180 Over The Next 5 Years
Pfizer Updates CHAMPIX To Add New Safety And Efficacy Data In European Union

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Phenytoin Chewable Tablets USP, 50 mg. This product is the generic version of Pfizer's Dilantin® Chewable Tablets, which are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. Phenytoin serum level determinations may be necessary for optimal dosage adjustments.

Posted-In: News FDA

 

Related Articles (MYL + PFE)

View Comments and Join the Discussion!